Patent · US Active

Stabilized Tat antigen and the use thereof for anti-HIV vaccination

US8501193B1 · kind B1 · utility

1Cited by

0References

29Claims

0Family size

Assignee

COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES · FR

Inventors

Pascal Drevet · Gif-sur-Yvette, FR
Evelyne Lajeunesse · Antony, FR
Alain Lecoq · Mennecy, FR
Michel Leonetti · Nozay, FR
Andre Menez · Voisins-le-Bretonneux, FR
Gervaise Moine · Montigny-le-Bretonneux, FR
Robert Thai · Nozay, FR

Key dates

Filing date	Apr 1, 2005
Grant date	Aug 6, 2013
Priority date	—
Expiry date	Nov 3, 2026

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/16322
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a vaccine composition comprising at least one type of anti-HIV vaccine composition containing at least one type of stabilized Tat antigen and to the use thereof for preventing and/or treating a human HIV infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.